IGF-1 LR3

IGF-1 LR3 (Long R3 Insulin-like Growth Factor 1) is a recombinant, engineered analogue of human insulin-like growth factor 1 (IGF-1). IGF-1 is a naturally occurring 70-amino-acid peptide hormone produced predominantly by the liver in response to growth hormone stimulation. IGF-1 LR3 is an 83-amino-acid molecule created by extending the native IGF-1 sequence with an additional 13 amino acids at the N-terminus. It also substitutes an arginine residue for the native glutamic acid at position 3, the “R3” of its name. It was developed in the 1990s by researchers investigating structure-activity relationships in the IGF/insulin family, notably groups working with GroPep Pty Ltd in Australia. It was intended as a laboratory and agricultural research tool rather than a therapeutic candidate.

In circulation, more than 99% of native IGF-1 is bound to one of six high-affinity IGF binding proteins (IGFBP-1 through IGFBP-6). These proteins sequester the hormone into a largely non-bioavailable pool and tightly regulate how much free IGF-1 is available to activate its receptor. The structural modifications in IGF-1 LR3 were specifically designed to reduce binding-protein affinity by roughly one to two orders of magnitude relative to native IGF-1. At the same time, they leave the IGF-1 receptor-binding surface intact. The practical consequence is a molecule that behaves, in cell culture and in animal models, largely as if IGFBPs were absent. A much larger fraction of administered IGF-1 LR3 remains free and receptor-available than would be the case for native IGF-1 at an equivalent dose.

This property has made IGF-1 LR3 a standard reagent in cell biology laboratories studying IGF-1 receptor signaling. It has separately drawn interest, including non-medical and unauthorized use, in strength-sport and bodybuilding communities for its purported anabolic properties. It is not an approved drug in any jurisdiction and has never completed human clinical trials. It is classified as a prohibited substance under the World Anti-Doping Agency (WADA) Prohibited List.

1. Reduced Binding-Protein Sequestration

The N-terminal 13-amino-acid extension and the glutamic-acid-to-arginine substitution at position 3 together reduce IGF-1 LR3’s affinity for the IGF binding proteins. This affinity drops by approximately one to two orders of magnitude compared with native IGF-1. The IGFBPs normally act as a circulating reservoir that limits how much IGF-1 reaches its receptor. This modification therefore increases the proportion of administered peptide available to bind and activate the type 1 IGF receptor (IGF-1R) at any given total concentration.

2. Full Agonism at the IGF-1 Receptor

IGF-1 LR3’s modifications are confined to the IGFBP-binding surface. The receptor-binding surface of the molecule is essentially unchanged from native IGF-1. As a result, IGF-1 LR3 retains full agonist activity at IGF-1R and produces equivalent downstream signaling to native IGF-1 in cells expressing the receptor. Ligand binding triggers receptor autophosphorylation and recruitment of insulin receptor substrate proteins (IRS-1, IRS-2) and Shc. This activates the PI3K/Akt/mTOR pathway, which drives protein synthesis, and the Ras/Raf/MEK/ERK pathway, which stimulates cell proliferation.

3. Cross-Reactivity with the Insulin Receptor

Like native IGF-1, IGF-1 LR3 retains weak affinity for the insulin receptor in addition to its primary IGF-1 receptor target. At sufficient concentrations, this cross-reactivity is believed to contribute to insulin-like effects on glucose uptake and disposal. This property was demonstrated directly in comparative animal studies described below, and it is central to the hypoglycemia risk associated with this class of molecule.

4. Suppression of the Endogenous GH/IGF-1 Axis

In several large-animal infusion studies, administration of IGF-1 LR3 reduced circulating concentrations of endogenous IGF-1, IGF-2, growth hormone, and IGFBP-3. This is consistent with negative feedback suppression of the animal’s own somatotropic axis (Conlon et al., 1995, J Endocrinol; Dunaiski et al., 1997, J Endocrinol). This feedback effect complicates any simple assumption that exogenous IGF-1 LR3 administration produces a purely additive increase in total growth-factor signaling.

Cell Studies

IGF-1 LR3 is used extensively as a cell culture reagent because its reduced IGFBP affinity allows sustained IGF-1 receptor activation. This avoids the repeated media supplementation that native IGF-1 requires, since native IGF-1 is rapidly sequestered by IGFBPs secreted into culture media by many cell types. In primary myoblast and satellite cell culture systems, IGF-1 receptor activation, whether by native IGF-1 or IGF-1 LR3, promotes proliferative expansion of satellite cells (PAX7-positive muscle progenitor cells) during the early culture phase.

It also supports myogenic differentiation and myotube formation during later stages. IGF-1 has been shown to increase cell-cycle progression factors during proliferation and to promote differentiation once cells exit the cell cycle. Concentrations reported in the literature for these assays typically range from approximately 10 to 100 nanograms/mL. The amount used depends on whether the goal is a sensitive signaling readout or full receptor saturation.

Animal Studies

Animal data on IGF-1 LR3 come almost entirely from agricultural and comparative physiology research rather than translational biomedical studies. In guinea pigs infused continuously for 7 days, IGF-1 LR3 (120 micrograms/day) increased the fractional weight of the adrenal glands, gut, kidneys, and spleen relative to controls. It also reduced circulating IGF-1, IGF-2, and IGF binding protein concentrations, and did not increase overall body weight gain (Conlon et al., 1995, J Endocrinol). In growing pigs, infusion of Long R3 IGF-1 reduced growth rate, plasma growth hormone, IGFBP-3, and endogenous IGF-1 concentrations relative to controls.

This outcome was attributed to feedback suppression of the pig’s own somatotropic axis (Dunaiski et al., 1997, J Endocrinol). In a comparative study in pigs and marmoset monkeys, IGF-1 variants with reduced IGFBP affinity, including LR3-type constructs, produced more potent and more prolonged hypoglycemic effects than native IGF-1 at matched doses. This directly demonstrates the insulin receptor cross-reactivity risk described above (Tomas et al., 1997, J Endocrinol).

Separately, a widely cited but mechanistically distinct study used viral-vector-mediated local overexpression of native IGF-1 (not injected IGF-1 LR3) in mouse skeletal muscle. It reported a 15% increase in muscle mass and a 14% increase in strength in young adult mice, with larger relative gains in aged mice. This illustrates the hypertrophic potential of sustained local IGF-1 receptor signaling, even though the study did not test the LR3 analogue itself (Barton-Davis et al., 1998, PNAS).

Human Clinical and Cosmetic Studies

No completed human clinical trials of IGF-1 LR3 have been published in the peer-reviewed literature, and no trials are registered on ClinicalTrials.gov. The only substantive human-relevant literature on IGF-1 LR3 comes from anti-doping science. Analytical chemists have developed immunopurification and mass-spectrometry methods to detect LR3IGF-1, Des(1-3)-IGF-1, and R3-IGF-1 in athlete plasma and black-market products.

This reflects documented unauthorized use in sport rather than any legitimate clinical research programme (Mongongu et al., 2021, Drug Test Anal). There is no human efficacy or safety data on IGF-1 LR3 obtained under controlled clinical conditions. Any claims about its effects in humans are extrapolated from animal and in vitro data rather than direct observation.

IGF-1 LR3 has not undergone formal human toxicology or safety evaluation. The clearest documented risk comes from comparative animal pharmacology. IGF-1 variants engineered to evade IGFBP sequestration, including LR3-type constructs, produce more potent and more prolonged hypoglycemia than native IGF-1 in pigs and marmoset monkeys at matched doses. This is attributed to increased free-hormone cross-reactivity with the insulin receptor (Tomas et al., 1997, J Endocrinol). IGF-1 receptor signaling through the PI3K/Akt and Ras/MAPK/ERK pathways is a well-established growth-promoting and anti-apoptotic mechanism implicated in several cancer types. Epidemiological studies have also associated chronically elevated endogenous IGF-1 with increased risk of certain cancers.

Because of this, there is a plausible theoretical concern that sustained, IGFBP-unrestrained IGF-1R activation could favor proliferation of transformed or pre-malignant cells. No dedicated carcinogenicity study of IGF-1 LR3 itself has been published. This concern remains extrapolated from the general biology of the IGF-1 signaling axis, rather than demonstrated directly for this analogue. No data exist on reproductive toxicity, long-term organ effects, or immunogenicity of IGF-1 LR3 in any species.

IGF-1 LR3’s defining pharmacological feature is an extended functional half-life relative to native IGF-1. This is a consequence of its reduced sequestration by, and clearance alongside, circulating IGF binding proteins. Native IGF-1 is cleared from plasma within minutes once dissociated from its binding proteins. Reported half-life estimates for IGF-1 LR3 vary across species, dose, and administration route. Values in the literature range from several hours after subcutaneous injection in rodent models to longer estimates in other contexts.

This variability reflects differences in study design rather than a single settled figure, and precise human pharmacokinetic data do not exist. In solution, IGF-1 LR3 is reported to be susceptible to aggregation and fragmentation at room temperature over a period of hours to a few days. Cold-chain storage (frozen, desiccated) is generally recommended for lyophilized material to preserve purity for research use.

IGF-1 LR3 is a structurally well-defined, mechanistically well-understood analogue of native IGF-1, engineered specifically to reduce IGF binding protein affinity while preserving full IGF-1 receptor agonism. Its in vitro pharmacology as a sustained IGF-1R activator is solid and widely used in cell biology research, particularly in myoblast and satellite cell studies. Its in vivo evidence base, however, is confined almost entirely to agricultural and comparative physiology studies in guinea pigs, pigs, and marmosets conducted in the 1990s. These studies demonstrate organ growth effects, feedback suppression of the endogenous GH/IGF-1 axis, and, notably, an increased and prolonged hypoglycemia risk relative to native IGF-1.

There is no published human clinical trial data on IGF-1 LR3. The only human-relevant literature concerns its detection as a doping agent. IGF-1 LR3 has no regulatory approval anywhere in the world and is prohibited under the WADA Prohibited List. Any claims about muscle-building or anabolic effects in humans rest on inference from animal and cell data rather than direct clinical evidence. The documented hypoglycemia risk in animal models, combined with the absence of human safety data, represents the most significant unresolved question for this compound.

Conlon et al., Journal of Endocrinology (1995), Long R3 IGF-1 infusion stimulates organ growth in the guinea pig

Dunaiski et al., Journal of Endocrinology (1997), Long R3 IGF-1 reduces growth, plasma GH, and IGFBP-3 in pigs

Tomas et al., Journal of Endocrinology (1997), IGF-I variants with poor IGFBP affinity show potent hypoglycemic action in pigs and marmosets

Barton-Davis et al., PNAS (1998), viral IGF-1 expression blocks age-related loss of skeletal muscle function

Mongongu et al., Drug Testing and Analysis (2021), detection of LongR3-IGF-I for antidoping purposes

1. Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995;146(2):247-253. doi: 10.1677/joe.0.1460247.

2. Dunaiski V, Dunshea FR, Walton PE, Goddard C. Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs. J Endocrinol. 1997;155(3):559-565.

3. Tomas FM, Walton PE, Dunshea FR, Ballard FJ. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. J Endocrinol. 1997;155(2):377-386. doi: 10.1677/joe.0.1550377.

4. Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA. 1998;95(26):15603-15607. doi: 10.1073/pnas.95.26.15603.

5. Mongongu C, Coudore F, Domergue V, Ericsson M, Buisson C, Marchand A. Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. Drug Test Anal. 2021;13(7):1256-1269. doi: 10.1002/dta.3016.